Journal
PHARMACOGENOMICS
Volume 11, Issue 1, Pages 89-103Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.09.154
Keywords
DMET; genome-wide association study; pharmacogenetics; pharmacokinetics; toxicity
Categories
Funding
- NIH, National Cancer Institute, Bethesda, MD, USA
- NATIONAL CANCER INSTITUTE [ZIABC010627] Funding Source: NIH RePORTER
Ask authors/readers for more resources
While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played - and will play - in future pharmacogenetics studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available